Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Trial of AD1208, a Cell Cycle Inhibitor/MASTL Inhibitor, as a Single Agent or a Combination in Subjects With Any Progressive, Locally Advanced(Unresectable) or Metastatic Solid Tumors

NCT06911333 is registered in ClinicalTrials.gov with Avelos Therapeutics Inc. as lead sponsor.

NCT NCT06911333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06911333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Trial of AD1208, a Cell Cycle Inhibitor/MASTL Inhibitor, as a Single Agent or a Combination in Subjects With Any Progressive, Locally Advanced(Unresectable) or Metastatic Solid Tumors
Lead sponsor
Avelos Therapeutics Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 11, 2025
Completion date
February 20, 2030
Enrollment
36 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, solid tumor cancer, solid tumor in advanced stage, solid tumor, adult, solid tumor, unspecified, adult, solid tumors refractory to standard therapy, tumor, solid